We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Thermo Fisher Scientific Inc | NYSE:TMO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.87 | 0.33% | 573.60 | 575.00 | 566.95 | 567.94 | 1,438,185 | 00:18:01 |
From Apr 2019 to Apr 2024
By Tess Stynes
NuVasive Inc. said Chairman and Chief Executive Alex Lukianov resigned after an investigation overseen by the medical-device company's board found he didn't comply with some of its expense reimbursement and other policies.
Shares fell 5.4% to $43.52 in recent premarket trading.
The company also said it expects its first-quarter revenue will exceed $190 million, above estimates of analysts polled by Thomson Reuters for $189 million. NuVasive added that it remains on track to meet its profit guidance for the year.
Greg Lucier, a member of NuVasive's board since 2013, was appointed as chairman and interim CEO. Mr. Lucier's previous experience includes serving from May 2003 to February 2014 as chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific in 2014.
NuVasive said that during Mr. Lucier's 11 years with Life Technologies, he led the company from being a small startup to a global biotech firm with nearly $4 billion in sales by 2013.
Regarding the investigation, NuVasive director Jack R. Blair said that although the amounts involved appear immaterial to the company's financial results that Mr. Lukianov's actions "in this regard were not representative of the high standards by which NuVasive operates."
The disclosure comes a day after Polycom Inc. agreed to pay the Securities and Exchange Commission $750,000 to settle civil charges that the tech company had inadequate internal controls and failed to report to investors that a former chief executive used nearly $200,000 of corporate funds for personal perks.
Polycom agreed to the settlement without admitting or denying the SEC's findings. Mr. Miller resigned as Polycom's CEO in July of 2013 after the company's audit committee found irregularities in his expense reports.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for NuVasive, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US6707041058
Access Investor Kit for Polycom, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US73172K1043
Access Investor Kit for Thermo Fisher Scientific, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US8835561023
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Thermo Fisher Scientific Chart |
1 Month Thermo Fisher Scientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
